The field of neuroscience received a significant boost as the Food and Drug Administration (FDA) cleared Pixyl.Neuro™, an innovative artificial intelligence (AI)-powered software designed to enhance the detection and follow-up of neurological disorders, including Alzheimer’s disease and multiple sclerosis (MS). By automating brain MRI analysis in under five minutes, Pixyl.Neuro allows for efficient quantification of brain region volume, enabling earlier identification of atrophy and assisting in the differential diagnosis.
With the introduction of adjunctive AI support, radiology workflows for the assessment of patients with neurological disorders can be reinforced. This recent FDA approval of Pixyl’s software has paved the way for improved diagnosis, management, and longitudinal follow-up of neurodegenerative and neuroinflammatory disorders. This development is particularly significant given the advent of disease-modifying treatments for MS, NMO (neuromyelitis optica), and Alzheimer’s disease.
Pixyl.Neuro has demonstrated its efficacy and impact worldwide, currently being utilized in over 12 countries. Since December 2022, its usage has witnessed an impressive four-fold increase, highlighting the growing recognition and appreciation for the software’s abilities.
FAQ:
1. What is Pixyl.Neuro?
Pixyl.Neuro is an AI-powered software that enhances the detection and follow-up of neurological disorders through automated brain MRI analysis.
2. How does Pixyl.Neuro’s AI support benefit radiology workflows?
Pixyl.Neuro’s AI support reinforces radiology workflows by aiding in the assessment of patients with neurological disorders and facilitating earlier identification of atrophy.
3. How many countries currently use Pixyl.Neuro?
Pixyl.Neuro is currently utilized in more than 12 countries worldwide.
While the FDA clearance for Pixyl.Neuro signifies a major advancement, it is essential to acknowledge that AI-based software is designed to assist healthcare professionals rather than replace their expertise. The synergy between AI and human intelligence will contribute to more accurate diagnoses, streamline patient management, and ultimately improve the lives of individuals living with neurological disorders.